Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody injection aims to tackle blinding eye diseases

NCT ID NCT05919693

Disease control Sponsor: EyeBiotech Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called EYE103, given as an injection into the eye, for people with diabetic macular edema (DME) or wet age-related macular degeneration (NVAMD). The trial had two parts: first, checking safety at increasing doses in about 12 people, then comparing two doses for effectiveness in about 80 people. The main goal was to see if the drug is safe and can improve vision.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EYE103 (a lab-made antibody given as an eye injection)
What this could lead to
If successful, EYE103 could offer a new treatment option for two common causes of vision loss, potentially reducing the need for frequent eye injections.
What could go wrong
This is an early-phase trial with only 33 participants, so results may not apply to everyone. The drug is injected directly into the eye, which carries risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

33 people

The number who actually took part.

Started

Jun 2023

Finished

Aug 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity * DME patients must be ≥ 18 years of age, NVAMD patients must be ≥ 50 years of age * Diagnosis of either DME or NVAMD. DME patients must be treatment naïve. NVAMD patients can be either treatment naïve or treatment experienced. * DME patients must have vision loss in the study eye * NVAMD patients can be either treatment-naïve or treatment experienced with vision loss in the study eye Exclusion Criteria: * Be pregnant or breastfeeding * History of cataract surgery and/or minimally invasive glaucoma surgery (MIGS) within 3 months of Screening * Yttrium-Aluminum Garnet (YAG) laser capsulotomy within 2 months of Screening * Any other condition except for DME or NVAMD or that could affect interpretation of study assessments

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic macular edema (DME) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic macular edema macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic macular edema (DME) Neovascular age-related macular degeneration (nvamd)

Contacts and locations

Locations

  • Abilene, TX

    Abilene, Texas, 79606, United States

  • Amarillo, TX

    Amarillo, Texas, 79109, United States

  • Arecibo, PR

    Arecibo, PR, 00612, Puerto Rico

  • Austin, TX

    Austin, Texas, 78705, United States

  • Bakersfield, CA

    Bakersfield, California, 93309, United States

  • Bellaire, TX

    Bellaire, Texas, 77401, United States

  • Caba, Argentina

    Caba, 1023, Argentina

  • Ciudad Autonoma Buenos Aires

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1121ABB, Argentina

  • Colorado Springs, Colorado

    Colorado Springs, Colorado, 80909, United States

  • Dallas, TX

    Dallas, Texas, 75231, United States

  • Germantown, TN

    Germantown, Tennessee, 38138, United States

  • Hagerstown, MD

    Hagerstown, Maryland, 21740, United States

  • Katy, TX

    Katy, Texas, 77494, United States

  • Knoxville, TN

    Knoxville, Tennessee, 37922, United States

  • Lakewood, CO

    Lakewood, Colorado, 80288, United States

  • Lemont, NV

    Lemont, Illinois, 60439, United States

  • London, England

    London, England, NW10 7NS, United Kingdom

  • London, UK

    London, W1G7LB, United Kingdom

  • McAllen, TX

    McAllen, Texas, 78503, United States

  • Modesto, CA

    Modesto, California, 95356, United States

  • Mountain View, CA

    Mountain View, California, 94040, United States

  • Nashville, TN

    Nashville, Tennessee, 37203, United States

  • Phoenix, AZ

    Phoenix, Arizona, 85032, United States

  • Plano, TX

    Plano, Texas, 75075, United States

  • Pompano Beach

    Pompano Beach, Florida, 33064, United States

  • Reno, NV

    Reno, Nevada, 89502, United States

  • Round Rock, TX

    Round Rock, Texas, 78681, United States

  • Sacramento, CA

    Sacramento, California, 95825, United States

  • Sacramento, CA

    Sacramento, California, 95841, United States

  • San Antonio, TX

    San Antonio, Texas, 78240, United States

  • The Woodlands, TX

    The Woodlands, Texas, 77384, United States

  • West Columbia, SC

    West Columbia, South Carolina, 29169, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.